Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 8: 50th year of the DMDG
Submit an article Journal homepage
1,343
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

The in vitro metabolism and in vivo pharmacokinetics of the bacterial β-glucuronidase inhibitor UNC10201652

Anna Kerinsa Cyprotex Discovery, Macclesfield, UKORCID Iconhttps://orcid.org/0000-0001-7851-7542
ORCID Icon,
Marta Koszyczareka Cyprotex Discovery, Macclesfield, UKORCID Iconhttps://orcid.org/0000-0003-4322-3338
ORCID Icon,
Caroline Smitha Cyprotex Discovery, Macclesfield, UK
,
Phil Butlera Cyprotex Discovery, Macclesfield, UKORCID Iconhttps://orcid.org/0000-0003-0449-4987
ORCID Icon,
Rob Rileya Cyprotex Discovery, Macclesfield, UK
,
Vamsi Madgulab DMPK and Toxicology, Sai Life Sciences Limited, Hyderabad, India
,
Nilkanth Naikb DMPK and Toxicology, Sai Life Sciences Limited, Hyderabad, India
,
Matthew R. Redinboc Departments of Chemistry, Biochemistry & Biophysics, and Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAORCID Iconhttps://orcid.org/0000-0003-0814-5346
ORCID Icon &
Ian D. Wilsond Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8558-7394
ORCID Icon show all
Pages 904-915 | Received 29 Jul 2022, Accepted 21 Sep 2022, Published online: 20 Dec 2022

References

  • Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. 1992. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med. 327(11):749–754.
  • Bhatt AP, Pellock SJ, Biernat KA, Walton WG, Wallace BD, Creekmore BC, Letertre MM, Swann JR, Wilson ID, Roques JR, et al. 2020. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy. Proc Natl Acad Sci U S A. 117(13):7374–7381.
  • Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. 1993. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 104(6):1832–1847.
  • Boelsterli UA, Ramirez-Alcantara V. 2011. NSAID acyl glucuronides and enteropathy. Curr Drug Metab. 12(3):245–252.
  • Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095.
  • Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB. 2006. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res. 23(3):533–539.
  • Houston JB, Carlile DJ. 1997. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev. 29(4):891–922.
  • Kilford PJ, Gertz M, Houston JB, Galetin A. 2008. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos. 36(7):1194–1197.
  • LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. 2012. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther. 341(2):447–454.
  • Pellock SJ, Creekmore BC, Walton WG, Mehta N, Biernat KA, Cesmat AP, Ariyarathna Y, Dunn ZD, Li B, Jin J, et al. 2018. Gut microbial β-glucuronidase inhibition via catalytic cycle interception. ACS Cent Sci. 4(7):868–879.
  • Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos. 33(9):1304–1311.
  • Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J. Pharm. Sci. 100(10):4090–4110.
  • Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, A Boelsterli UA. 2014. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica. 44(1):28–35.
  • Smith R, Jones RDO, Ballard PG, Griffiths HH. 2008. Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog. Xenobiotica. 38(11):1386–1398.
  • Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T. 1996. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56(16):3752–3757.
  • Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh L-A, Mani S, et al. 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 330(6005):831–835.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.